-
Diagnostics World News | Illumina today announced that its Board of Directors has appointed Jacob Thaysen, Ph.D., senior vice president of Agilent Technologies and president of its Life Sciences and Applied Markets Group, as Illumina’s next Chief Executive Officer, effective September 25, 2023.
Sep 5, 2023
-
Diagnostics World | Medicare, the single largest payer for healthcare in the United States, has a hodgepodge of national and state policies capable of bankrupting innovation in molecular diagnostics. It is an inequitable, fiscally perplexing, needlessly verbose, and fraud-prone system but, if there’s a bright spot, it’s the Molecular Diagnostic Services Program (MolDX) responsible for technology assessments and claims disbursement for more than half the country.
Sep 5, 2023
-
Diagnostics World | Illumina and Pillar partner up to make Pillar’s oncology assays commercially available on a global scale; C2N Diagnostics releases the PrecivityAD2 blood test, a clinical care assay that meets the standard of care with currently available PET scans and cerebrospinal fluid tests; University of Missouri researchers developed an innovative method using nanopores; more.
Aug 31, 2023
-
Diagnostics World | ADARx Pharmaceuticals will use financing for treatment of a broad range of diseases; A-Alpha Bio plans to use Series A2 funding to accelerate antibody discovery and development for emerging biothreats, including HIV; Cytomos will scale-up market testing of its technology platform for cell analysis; more.
Aug 30, 2023
-
Diagnostics World | The U.S. Food and Drug Administration (FDA) has been making moves signaling its intention to better align the regulatory framework for companion diagnostics (CDx) to what is happening in real-world clinical practice.
Aug 24, 2023